Study shows Peregrine's bavituximab can cure lethal virus infections

Peregrine Pharmaceuticals, Inc. today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.

Read the whole article on Physorg

More from Physorg